Daniel J. Starks - Apr 25, 2025 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: Director
Signature: /s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Apr 25, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/29/2025, 06:22 PM
Previous filing: Apr 30, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+1.64K	+0.02%	$0.00	6.73M	Apr 25, 2025	Direct	F1
holding	ABT	Common shares without par value						258	Apr 25, 2025	Alynne Starks 2012 Irrevocable Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+4.52K		$0.00	4.52K	Apr 25, 2025	Common Shares	4.52K	$128.40	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2	Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F3	Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.